Probiotic products containing Bacillus species of spores are normally formulated in the form of capsules, tablets or dry formulations. Bacilliq is a unique syrup formulation for direct consumption. Bacilliq syrup formulation does not require cold chain storage and transportation.
Bacilliq is manufactured by Synergia Life Sciences Pvt. Ltd., (a Virids Group Company) under patents filed.
Bacilliq syrup is a clear, transparent liquid formulation. It contains HU58 spores, a well documented, identified and characterized strain of Bacillus subtilis licensed to Viridis BioPharma Pvt. Ltd., from Royal Holloway, University of London.
6 months Accelerated Stability studies of Bacilliq syrup shows that formulation remains stable under 40°C and 75% relative humidity (RH) conditions with no drop in probiotic count. Further the appearance, taste and flavor is also maintained with no spoilage due to growth of pathogens such as E.coli.
Bacilliq syrup can be prepared in a variety of flavors and varying concentrations of HU58 Bacillus subtilis. Synergia can also use this syrup formulation technology to develop probiotic liquid formulations for other strains of Bacillus species. Synergia can supply sugar free compositions also.
